tert-Butyl (2S,4S)-N-tert-butoxycarbonyl-4-hydroxymethylprolinate | 163190-47-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-Butyl (2S,4S)-N-tert-butoxycarbonyl-4-hydroxymethylprolinate
• 英文别名: (2S,4S)-N-tert-butoxycarbonyl-2-tert-butoxycarbonyl-4-hydroxymethylpyrrolidine；(2S,4S)-4-hydroxymethyl-pyrrolidine-1,2-dicarboxylic acid di-tert-butyl ester；(4S)-1-(tert-Butyloxycarbonyl)-4-(Hydroxymethyl)-L-Proline tert-Butyl Ester；ditert-butyl (2S,4S)-4-(hydroxymethyl)pyrrolidine-1,2-dicarboxylate
• CAS: 163190-47-4
• 化学式: C₁₅H₂₇NO₅
• 分子量: 301.383
• InChiKey: PJDYQKZRLWYKCC-QWRGUYRKSA-N

物化性质

• 沸点：
  383.2±27.0 °C(Predicted)
• 密度：
  1.105±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-Butyl (2S,4S)-N-tert-butoxycarbonyl-4-hydroxymethylprolinate 在 盐酸 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 (2S,4S)-4-(3-chloro-phenoxymethyl)-pyrrolidine-2-carboxylic acid hydrochloride salt
  参考文献：
  名称：

  Part 3: Design and synthesis of proline-derived α2δ ligands

  摘要：

  A potent series of substituted (2S,4S)-benzylproline alpha(2)delta ligands have been designed from the readily available starting material (2S,4R)-hydroxy-L-proline. The ligands have improved pharmacokinetic profile over the (4S)-phenoxyproline derivatives described previously and have potential for development as oral agents for the treatment of neuropathic pain. Compound 16 has been progressed to clinical development. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.058
• 作为产物：
  描述：

  (2S,4S)-N-tert-butoxycarbonyl-2-tert-butoxycarbonyl-4-carboxyl pyrrolidine 在 sodium tetrahydroborate 、 水 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 tert-Butyl (2S,4S)-N-tert-butoxycarbonyl-4-hydroxymethylprolinate
  参考文献：
  名称：

  Preparation method for pyrrolidine-2-carboxylic acid derivatives

  摘要：

  本发明涉及医药合成领域，特别是一种吡咯烷-2-羧酸衍生物的制备方法。本发明采用以下技术方案：提供具有结构式（E）的化合物，其中R为R1或R2，R1为C1-C6烷基、苄基、对甲氧基苄基或对硝基苄基，R2为氢；R3为羧基的保护基；P1为氮上的保护基。

  公开号：

  US20160145208A1

文献信息

• Substituted saturated aza heterocycles as inhibitors of nitric oxide
  申请人：Merck & Co., Inc.

  公开号：US05821261A1

  公开（公告）日：1998-10-13

  Disclosed herein are compounds of Formula (I) ##STR1## and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These disease and disorders include hypotension, septic shock, toxic shock syndrom, hemodialysis, IL-2 therapy such as in cancer patients, cachexia, immnunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn or psoriasis and respiratory conditions such as bronchitis, asthma, and acure respiratory distress (ARDS), myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis. Compounds of Formula I are also useful in the treatment of hypoxia, hyperbaric oxygen convulsions and toxicity, dementia, Sydenham's chorea, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, Korsakoffs disease, imbecility related to cerebral vessel disorder, ischemic brain edema, sleeping disorders, schizophrenia, depression, PMS, anxiety, drug addiction, pain, migraine, immune complex disease, as immunosupressive agents and for preventing or reversing tolerance to opiates and diazepines.

  披露的是公式(I)化合物##STR1##及其药学上可接受的盐，发现这些化合物在治疗一氧化氮合酶介导的疾病和紊乱方面有用，包括神经退行性疾病、胃肠动力障碍和炎症。这些疾病和紊乱包括低血压、败血症休克、毒性休克综合征、血液透析、IL-2治疗（如癌症患者）、恶病质、免疫抑制（如移植治疗）、自身免疫和/或炎症迹象，包括晒伤或银屑病和呼吸系统疾病，如支气管炎、哮喘、急性呼吸窘迫综合症（ARDS）、心肌炎、心力衰竭、动脉硬化、关节炎、类风湿性关节炎、慢性或炎症性肠病、溃疡性结肠炎、克罗恩病、系统性红斑狼疮（SLE）、眼科疾病，如青光眼和葡萄膜炎、1型糖尿病、胰岛素依赖型糖尿病和囊性纤维化。公式I的化合物在治疗缺氧、高压氧惊厥和毒性、痴呆、Sydenham舞蹈病、帕金森病、亨廷顿病、肌萎缩侧索硬化、多发性硬化、科尔萨科夫病、与脑血管障碍相关的愚笨、缺血性脑水肿、睡眠障碍、精神分裂症、抑郁症、经前综合症、焦虑、药物成瘾、疼痛、偏头痛、免疫复合物疾病，作为免疫抑制剂，以及用于预防或逆转对阿片类药物和苯二氮䓬类药物的耐受性。
• [EN] PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT<br/>[FR] DERIVES DE PROLINE PRESENTANT UNE AFFINITE POUR LA SOUS-UNITE ALPHA-2-DELTA DU CANAL DE CALCIUM
  申请人：PFIZER LTD

  公开号：WO2004039367A1

  公开（公告）日：2004-05-13

  The compounds of formula (I) or a pharmaceutically acceptable salt, solvate or pro-drug thereof, are proline derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, fibromyalgia, arthritis, neuropathalogical disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. Wherein either X is O, S, NH or CH2 and Y is CH2 or a direct bond, or Y is O, S or NH and X is CH2; and R is a 3-12 membered cycloalkyl, 4-12 membered heterocycloalkyl, heteroaryl or aryl, where any ring may be optionally substituted with one or more substituents independently selected from halogen, hydroxy, cyano, nitro, amino, hydroxycarbonyl, Cl-C6 alkyl, Cl-C6 alkenyl, CI-C6 alkynyl, Cl-C6 alkoxy, hydroxyC,-C6 alkyl, Cl-C6 alkoxyC,-C6 alkyl, perfluoro Cl-C6 alkyl, perfluoroC,-C6 alkoxy, Cl-C6 alkylamino, di- C1-C6 alkylamino, aminoC1-C6 alkyl, Cl-C6 alkylaminoC,-C6 alkyl, di-Cl-C6 alkylaminoC,-C6 alkyl, CI-C6acyl, C1-C6acyloxy, Cl-C6acyloxyC,-C6 alkyl, Cl-C6 acylamino, Cl-C6 alkylthio, C1-C6 alkylthiocarbonyl, C1-C6 alkylthioxo, C1-C6 alkoxycarbonyl, Cl-C6 alkylsulfonyl, C1-C6 alkylsulfonylamino, aminosulfonyl, Cl-C6 alkylaminosulfonyl, di-Cl-C6 alkylaminosulfonyl, 3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl; or a pharmaceutically acceptable salt, solvate or pro-drug thereof.

  化学式（I）的化合物或其药学上可接受的盐、溶剂化合物或前药是脯氨酸衍生物，在治疗癫痫、晕厥发作、运动减退、颅内疾病、神经退行性疾病、抑郁症、焦虑、恐慌、疼痛、纤维肌痛、关节炎、神经病理性疾病、睡眠障碍、内脏疼痛疾病和胃肠疾病的治疗中有用。包括制备最终产品和在过程中有用的中间体的方法。还包括含有一种或多种该化合物的药物组合物。其中X为O、S、NH或CH2，Y为CH2或直接键，或Y为O、S或NH，X为CH2；R为3-12环状烷基、4-12环状杂环烷基、杂芳基或芳基，其中任何环都可以选择性地用一个或多个取代基独立选择自卤素、羟基、氰基、硝基、氨基、羟基羰基、Cl-C6烷基、Cl-C6烯基、Cl-C6炔基、Cl-C6烷氧基、羟基C1-C6烷基、Cl-C6烷氧基C1-C6烷基、全氟Cl-C6烷基、全氟C1-C6烷氧基、Cl-C6烷基氨基、二-Cl-C6烷基氨基、氨基C1-C6烷基、Cl-C6烷基氨基C1-C6烷基、二-Cl-C6烷基氨基C1-C6烷基、Cl-C6酰基、C1-C6酰氧基、Cl-C6酰氧基C1-C6烷基、Cl-C6酰胺基、Cl-C6烷基硫基、C1-C6烷基硫羰基、C1-C6烷基硫氧基、C1-C6烷氧羰基、Cl-C6烷基磺基、C1-C6烷基磺酰胺基、氨基磺基、Cl-C6烷基氨基磺基、二-Cl-C6烷基氨基磺基、3-8环状烷基、4-8环状杂环烷基、苯基和单环杂芳基；或其药学上可接受的盐、溶剂化合物或前药。
• Therapeutic proline derivatives
  申请人：——

  公开号：US20040132801A1

  公开（公告）日：2004-07-08

  The compounds of formula (I) or a pharmaceutically acceptable salt, solvate or pro-drug thereof, are proline derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, fibromyalgia, arthritis, neuropathalogical disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. 1 wherein either X is O, S, NH or CH 2 and Y is CH 2 or a direct bond, or Y is O, S or NH and X is CH 2 ; and R is a 3-12 membered cycloalkyl, 4-12 membered heterocycloalkyl, heteroaryl or aryl, where any ring may be optionally substituted with one or more substituents independently selected from halogen, hydroxy, cyano, nitro, amino, hydroxycarbonyl, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 alkoxy, hydroxyC 1 -C 6 alkyl, C 1 -C 6 alkoxyC 1 -C 6 alkyl, perfluoro C 1 -C 6 alkyl, perfluoroC 1 -C 6 alkoxy, C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, aminoC 1 -C 6 alkyl, C 1 -C 6 alkylaminoC 1 -C 6 alkyl, di-C 1 -C 6 alkylaminoC 1 -C 6 alkyl, C 1 -C 6 acyl, C 1 -C 6 acyloxy, C 1 -C 6 acyloxyC 1 -C 6 alkyl, C 1 -C 6 acylamino, C 1 -C 6 alkylthio, C 1 -C 6 alkylthiocarbonyl, C 1 -C 6 alkylthioxo, C 1 -C 6 alkoxycarbonyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkylsulfonylamino, aminosulfonyl, C 1 -C 6 alkylaminosulfonyl, di-C 1 -C 6 alkylaminosulfonyl, 3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl; or a pharmaceutically acceptable salt, solvate or pro-drug thereof.

  公式（I）的化合物或其药学上可接受的盐、溶剂合物或前药是脯氨酸衍生物，可用于治疗癫痫、晕厥发作、低动力症、头颅疾病、神经退行性疾病、抑郁症、焦虑症、惊恐症、疼痛、纤维肌痛、关节炎、神经病理学疾病、睡眠障碍、内脏疼痛疾病和胃肠疾病的治疗。包括用于制备最终产品和在过程中有用的中间体的过程。还包括含有一种或多种化合物的制药组合物。其中，X为O、S、NH或CH2，Y为CH2或直接键，或Y为O、S或NH，X为CH2；R为3-12环烷基、4-12杂环烷基、杂环芳基或芳基，其中任何环都可以选择地用一个或多个取代基独立地选择自卤素、羟基、氰基、硝基、氨基、羟基羰基、C1-C6烷基、C1-C6烯基、C1-C6炔基、C1-C6烷氧基、羟基C1-C6烷基、C1-C6烷氧基C1-C6烷基、全氟C1-C6烷基、全氟C1-C6烷氧基、C1-C6烷基氨基、二C1-C6烷基氨基、氨基C1-C6烷基、C1-C6烷基氨基C1-C6烷基、二C1-C6烷基氨基C1-C6烷基、C1-C6酰基、C1-C6酰氧基、C1-C6酰氧基C1-C6烷基、C1-C6酰氨基、C1-C6烷硫基、C1-C6烷硫酰基、C1-C6烷基磺酰氨基、氨基磺酰基、C1-C6烷基氨基磺酰基、二C1-C6烷基氨基磺酰基、3-8环烷基、4-8杂环烷基、苯基和单环杂芳基；或其药学上可接受的盐、溶剂合物或前药。
• PREPARATION METHOD FOR PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES
  申请人：Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

  公开号：EP3015456A1

  公开（公告）日：2016-05-04

  The present invention relates to the field of medical synthesis, in particular to a preparation method for pyrrolidine-2-carboxylic acid derivatives. The present invention adopts the following technical solution: providing a compound having a structure of formula (E), wherein R is R1 or R2, R1 is C1-C6 an alkyl, benzyl, p-methoxybenzyl, or p-nitrobenzyl group, and R2 is hydrogen; R3 is a protecting group of the carboxyl group; and P1 is a protecting group on nitrogen.

  本发明涉及医药合成领域，尤其涉及一种吡咯烷-2-羧酸衍生物的制备方法。本发明采用如下技术方案：提供一种具有式（E）结构的化合物，其中R为R1或R2，R1为C1-C6的烷基、苄基、对甲氧基苄基或对硝基苄基，R2为氢；R3为羧基的保护基；P1为氮上的保护基。
• Synthesis of (2S,4S)- and (2S,4R)-5,5′-dihydroxy[5,5-²H₂]leucine by two independent routes
  作者：Xavier Durand、Piétrick Hudhomme、Jeffrey A. Khan、Douglas W. Young

  DOI：10.1039/p19960001131

  日期：——

  In studies directed at discovering the absolute stereochemistry of the reaction catalysed by the enzyme glutamate gamma-carboxylase, two independent stereoselective syntheses of (2S,4S)-5,5'-dihydroxy[5,5-H-2(2)]leucine 4a and its (2S,4R)-diastereoisomer 4b have been developed. The first synthesis uses (2S)-pyroglutamic acid as starting material and provides (2S,4S)-5,5'-dihydroxy[-5,5-H-2(2)]leucine 4a, while the second starts with (2S,4R)-4-hydroxyproline and provides (2S,4R)-5,5'-dihydroxy[5,5-H-2(2)] leucine 4b.